Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 213.63B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | 850.32M |
| EPS (ttm) | 11.74 |
| PE Ratio | 21.21 |
| Forward PE | 12.27 |
| Dividend | 9.70 (3.89%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 1,388,746 |
| Average Volume | 855,281 |
| Open | 248.10 |
| Previous Close | 248.60 |
| Day's Range | 244.40 - 252.00 |
| 52-Week Range | 231.90 - 313.80 |
| Beta | 0.17 |
| RSI | 36.68 |
| Earnings Date | Jul 24, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche gets FDA clearance for respiratory test to detect viruses
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III A...
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase II...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. Latest Ratings ... Full story available on Benzinga.com
Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Confer...
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being pres...
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.
Roche Holding AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q2 earnings call.
Roche Holding AG (RHHBY) Q2 2025 Earnings Call Transcript
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (del...
Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
Lead With Us -- a promise for innovative partnerships, better insights, faster support, and improved healthcare outcomes. INDIANAPOLIS and CHICAGO , July 24, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; ...
Significant amount of U.S. investment pledged, says Roche CEO
Thomas Schinecker, CEO of Roche, discusses the company's earnings and what the pharmaceutical industry in Europe is doing to win favour with the Trump administration.
Roche eyes direct-to-patient sales in U.S. to avoid pharma middlemen
Roche considering selling drugs directly to US patients, CEO says
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part of talks with the U.S. government, which is pressuring drugmakers to cut p...
Roche Holding Non-GAAP EPS of CHF 11.08, revenue of CHF 30.94B
Roche confirms guidance as H1 core operating profit up 6%
Swiss drugmaker Roche reported first-half operating profit up 6% on Thursday at a forecast-beating 12 billion Swiss francs ($15.15 billion) and also confirmed its full-year outlook.
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines. Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (bre...
The Roche Associates, Inc. Named “Top Senior Living Marketing Agency 2025”
East Longmeadow, MA, July 23, 2025 (GLOBE NEWSWIRE) -- The Roche Associates, Inc. was recently named “Top Senior Living Marketing Agency for 2025” by Elder Care Review. The Roche Associates, Inc. emer...